UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000040501
Receipt No. R000046228
Scientific Title Post-Trial Observational Study for JHN002 (A Phase II Clinical Trial of the Combination of SPM-011 and BNCT Treatment System (BNCT30) in Patients With Unresectable Locally Recurrent Head and Neck Squamous Cell Carcinoma or Unresectable Head and Neck Non-Squamous Cell Carcinoma): JHN002 Look Up Study
Date of disclosure of the study information 2020/05/23
Last modified on 2020/05/23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Post-trial observational study for a phase II study of accelerator-BNCT for head and neck cancer (JHN002): JHN002 Look Up Study
Acronym JHN002 Look Up Study
Scientific Title Post-Trial Observational Study for JHN002 (A Phase II Clinical Trial of the Combination of SPM-011 and BNCT Treatment System (BNCT30) in Patients With Unresectable Locally Recurrent Head and Neck Squamous Cell Carcinoma or Unresectable Head and Neck Non-Squamous Cell Carcinoma): JHN002 Look Up Study
Scientific Title:Acronym JHN002 Look Up Study
Region
Japan

Condition
Condition Unresectable locally recurrent head and neck squamous cell carcinoma
Unresectable head and neck non-squamous cell carcinoma
Classification by specialty
Hematology and clinical oncology Oto-rhino-laryngology Radiology
Adult
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The objective of this clinical study is to evaluate the efficacy and safety of boron neutron capture therapy (BNCT) using SPM-011 and BNCT30 in patients with unresectable locally recurrent head and neck squamous cell carcinoma or unresectable head and neck non-squamous cell carcinoma with long observation period.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes - Locoregional progression-free survival
Time from the date of BNCT to first documented disease progression in locoregional area.
Key secondary outcomes - Efficacy
- Duration of response
The duration of the response is the time from the confirmed achievement of CR or PR (whichever is recorded first) to the date of initial objectively confirmed recurrence or exacerbation.
- Response
The objective tumor response within 2 years of BNCT is evaluated using RECIST guidelines (version 1.1). Change in tumor size is evaluated as the proportion of tumo size in target lesions compared to baseline before BNCT.
- Overall survival
Time from the date of BNCT todeath from any cause up to the completion of the survival survey period.
- Safety
- Adverse events
Incidence and grading in the observation period

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Patients who have signed written informed consent to participate in the post-trial observational study on their own free will.
2. Patients who were registered in JHN002 trial and treated with BNCT, and meeting at least one of the following conditions:
1) Patients whose follow-up period in JHN002 trial was ended
2) Patients whose follow-up period in JHN002 trial was discontinued without assessment of PD for some reason, and who consented to continuous follow-up at a BNCT facility. The reasons for discontinuation of follow-up in JHN002 trial will be expected that:
- The investigators confirm the increase in tumor size by macroscopic findings, endoscopic findings, and ultrasonography, before PD assessment by diagnostic imaging.
- The investigators intend further antitumor treatment in the future.
- The investigators intend to conduct unapproved fluoride-18 fluoroborono- phenylalanine positron emission tomography (18F-FBPA-PET) study.
Key exclusion criteria 1. Patients unable to comply with the protocol and to attend follow-up visits (because of mental, family, social, geographical, or other reasons).
Target sample size 21

Research contact person
Name of lead principal investigator
1st name Katsumi
Middle name
Last name Hirose
Organization Southern Tohoku BNCT Research Center
Division name Department of Radiation Oncology
Zip code 963-8052
Address 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052 JAPAN
TEL +81-24-934-5330
Email khirose@hirosaki-u.ac.jp

Public contact
Name of contact person
1st name Katsumi
Middle name
Last name Hirose
Organization Southern Tohoku BNCT Research Center
Division name Department of Radiation Oncology
Zip code 963-8052
Address 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052 JAPAN
TEL +81-24-934-5330
Homepage URL
Email khirose@hirosaki-u.ac.jp

Sponsor
Institute Southern Tohoku BNCT Research Center
Institute
Department

Funding Source
Organization Southern Tohoku BNCT Research Center
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Southern Tohoku General Hospital
Address 7-115 Yatsuyamada, Koriyama, Fukushima JAPAN
Tel +81-24-934-5322
Email bnct.irb@mt.strins.or.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 05 Month 23 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 21
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2016 Year 05 Month 18 Day
Date of IRB
2016 Year 05 Month 30 Day
Anticipated trial start date
2016 Year 06 Month 01 Day
Last follow-up date
2023 Year 05 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Observation and surveys
After obtaining the subject's consent, the investigator of the medical institution will perform observation, surveys at the timing specified in "Timing of observation and surveys."

Timing of observation and surveys
Medical examination by physician
At every 3 months until 2 years, the investigator will examine the subject for anomalies by visual examination, palpation, and with a stethoscope and tapping.

CT/MRI examination
At every 3 months until 2 years, CT or MRI of the head and neck region will be performed, as much as possible, with a contrast medium.
Throughout the trial period, the examination methods and procedures must not be changed.
The investigators will evaluate the data according to the RECIST guidelines (version 1.1).

Observation of the skin at the irradiation site
At every 3 months until 2 years, the skin condition at the irradiation site will be observed.
To evaluate safety for the skin tissue at the irradiation site following BNCT, the skin at the irradiation site will be evaluated according to the grading system for dermatitis radiation defined in CTCAE v4.0.

Observation of the mucosa at the irradiation site
At every 3 months until 2 years, the mucosal condition at the irradiation site will be observed.
The condition of mucosa at the irradiation site will be evaluated according to CTCAE v4.0.

Adverse events
All adverse events to the end of the post-trial follow-up period (at the time of discontinuation of the observational study) will be recorded in the medical record. Ongoing adverse events at the end of the post-observation period will be traced until the adverse event concerned remains to be unchanged or resolving, or the post-trial follow-up period for the subject concerned ends.

Confirmation of survival
Taking the day of BNCT as the beginning date of overall survival calculation for each subject, the survival of each subject will be surveyed until 5 years after BNCT.

Management information
Registered date
2020 Year 05 Month 23 Day
Last modified on
2020 Year 05 Month 23 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046228

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.